These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 12942854)
1. [Preclinical evaluation of the safety of biotechnology products: specific aspects]. Descotes J; Ravel G; Vial T Therapie; 2003; 58(2):139-43. PubMed ID: 12942854 [TBL] [Abstract][Full Text] [Related]
2. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Serabian MA; Pilaro AM Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669 [TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]
4. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. Snodin DJ; Ryle PR BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349 [TBL] [Abstract][Full Text] [Related]
5. Issues with biotechnology products in toxicologic pathology. Terrell TG; Green JD Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366 [TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Singh SS Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106 [TBL] [Abstract][Full Text] [Related]
7. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals. Pilling AM Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549 [TBL] [Abstract][Full Text] [Related]
8. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells. Lebrec H; Narayanan P; Nims R J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744 [TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of biotechnology products. Zbinden G Drug Saf; 1990; 5 Suppl 1():58-64. PubMed ID: 2182064 [TBL] [Abstract][Full Text] [Related]
10. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Brennan FR; Shaw L; Wing MG; Robinson C Mol Biotechnol; 2004 May; 27(1):59-74. PubMed ID: 15122047 [TBL] [Abstract][Full Text] [Related]
11. The relevance of pharmacokinetics in the development of biotechnology products. Toon S Eur J Drug Metab Pharmacokinet; 1996; 21(2):93-103. PubMed ID: 8839682 [TBL] [Abstract][Full Text] [Related]
12. Nonclinical development of biopharmaceuticals. Baumann A Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058 [TBL] [Abstract][Full Text] [Related]
14. Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. An attempt to transfer current experience into future testing strategies. Teelmann K; Hohbach C; Lehmann H Arch Toxicol; 1986 Dec; 59(4):195-200. PubMed ID: 3548648 [TBL] [Abstract][Full Text] [Related]
15. Preclinical safety of biotechnology products intended for human use. Proceedings of a satellite symposium of the IV International Congress of Toxicology. Tokyo, Japan, July 26, 1986. Prog Clin Biol Res; 1987; 235():1-213. PubMed ID: 3601998 [No Abstract] [Full Text] [Related]
17. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung. Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137 [TBL] [Abstract][Full Text] [Related]
18. Immunotoxicology: role in the safety assessment of drugs. Descotes J Drug Saf; 2005; 28(2):127-36. PubMed ID: 15691223 [TBL] [Abstract][Full Text] [Related]